Ceftizoxime
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Ceftizoxime: From Broad-Spectrum Antibacterial Therapy to Gonococcal Urethritis
One-Sentence Summary
Ceftizoxime is a third-generation cephalosporin antibiotic with established broad-spectrum antibacterial activity, originally developed for treatment of serious gram-negative bacterial infections. The TxGNN model predicts it may be effective for Gonococcal Urethritis, with 0 registered clinical trials and 11 publications (including 1 direct head-to-head RCT vs. ceftriaxone) currently supporting this direction. This prediction is strongly mechanistically grounded, as ceftizoxime’s beta-lactam mechanism directly targets the cell wall synthesis pathway of Neisseria gonorrhoeae, including penicillinase-producing strains (PPNG).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Broad-spectrum bacterial infections (third-generation cephalosporin) |
| Predicted New Indication | Gonococcal Urethritis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L2 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Ceftizoxime is a third-generation cephalosporin antibiotic that exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs), thereby inhibiting the final transpeptidation step of bacterial cell wall peptidoglycan synthesis. Critically, ceftizoxime is highly stable against beta-lactamase hydrolysis, which gives it activity against penicillinase-producing strains of Neisseria gonorrhoeae (PPNG) — strains that have rendered traditional penicillin therapy ineffective.
Neisseria gonorrhoeae, the causative organism of gonococcal urethritis, is a gram-negative diplococcus whose susceptibility to beta-lactam antibiotics is entirely dependent on the drug’s affinity for gonococcal PBP2 and its resistance to beta-lactamase degradation. In vitro studies show ceftizoxime achieves an MIC₉₀ of 0.004 µg/mL against N. gonorrhoeae — well below clinically achievable serum concentrations following intramuscular injection. This places ceftizoxime pharmacodynamically on par with ceftriaxone, the current CDC-recommended agent.
The prediction is therefore not a speculative repurposing but a mechanistically direct extension: ceftizoxime’s structural features that confer beta-lactamase stability and high PBP affinity are exactly the pharmacological properties required to treat PPNG-associated urethritis. The available clinical literature, including a direct head-to-head RCT comparing ceftizoxime with ceftriaxone (PMID 1948517), further validates this rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1948517 | 1991 | RCT | Sexually Transmitted Diseases | Head-to-head comparison of single-dose ceftizoxime vs. ceftriaxone for uncomplicated urethral gonorrhea; both agents showed equivalent efficacy including against PPNG strains |
| 2264006 | 1990 | Prospective Clinical Study | Sexually Transmitted Diseases | 175 male patients with confirmed gonococcal urethritis treated with single-dose ceftizoxime in LA (area with >1% PPNG prevalence); demonstrated efficacy as alternative to ceftriaxone |
| 6324399 | 1984 | Prospective Clinical Study | Sexually Transmitted Diseases | 55 men with culture-confirmed gonococcal urethritis (including 47% PPNG) treated with 1 g IM ceftizoxime; 100% cure rate with no local or systemic adverse effects |
| 6092006 | 1984 | In vitro/In vivo Susceptibility Study | Chemotherapy | Tested 102 freshly isolated N. gonorrhoeae strains (>50% partially/fully penicillin-resistant); MIC₉₀ of ceftizoxime = 0.004 µg/mL, demonstrating superior activity vs. penicillin |
| 6325750 | 1983 | Clinical Evaluation | Japanese Journal of Antibiotics | 41 male patients with gonorrheal urethritis (15% PPNG) treated with ceftizoxime + probenecid; bacteriological and clinical evaluation of PPNG vs. non-PPNG strains |
| 11406757 | 2001 | Resistance Surveillance | Journal of Infection and Chemotherapy | Reports emergence of cephem/aztreonam-resistant N. gonorrhoeae that does not produce beta-lactamase; raises alert regarding monitoring for ceftizoxime resistance development |
| 23416957 | 2013 | Case Report / Phenotypic Characterization | Journal of Antimicrobial Chemotherapy | First two ESC-resistant N. gonorrhoeae cases in South Africa associated with cefixime treatment failure; relevant context for monitoring extended-spectrum cephalosporin resistance |
| 2122657 | 1990 | Clinical Efficacy Study (comparator) | Acta Urologica Japonica | Epidemiological study of 109 gonococcal infections; evaluates cefetamet pivoxil as alternative agent — provides indirect evidence for third-generation cephalosporin class effect |
| 1416861 | 1992 | Clinical Study (comparator) | Antimicrobial Agents and Chemotherapy | Dose-response study of oral cefpodoxime proxetil in male gonococcal urethritis; 100% eradication across all doses — supports third-generation cephalosporin class efficacy |
| 2673664 | 1989 | Large Cohort (comparator) | Current Medical Research and Opinion | 1,000-patient trial of cefetamet pivoxil showing single-dose efficacy in gonorrhea; comparative data reinforces class-level evidence |
India Market Information
Ceftizoxime currently has no registered products in India (market status: not marketed). There are no authorization records to display.
Safety Considerations
Drug Interactions (12 moderate-level interactions identified, source: DDInter):
| Interacting Drug | Level | Clinical Note |
|---|---|---|
| Kanamycin | Moderate | Aminoglycoside combination — monitor for additive nephrotoxicity/ototoxicity |
| Neomycin | Moderate | Aminoglycoside combination — monitor renal function |
| Streptomycin | Moderate | Aminoglycoside combination — monitor renal function |
| Amikacin | Moderate | Aminoglycoside combination — monitor renal function |
| Amikacin (liposomal) | Moderate | Aminoglycoside combination — monitor renal function |
| Gentamicin | Moderate | Aminoglycoside combination — monitor renal function |
| Warfarin | Moderate | Beta-lactams may enhance anticoagulant effect; monitor INR |
| Chloramphenicol | Moderate | Potential antagonism with bacteriostatic agents against bactericidal cephalosporins |
| Ethinylestradiol | Moderate | Antibiotic may reduce enterohepatic recirculation of estrogen; advise additional contraceptive precautions |
| Mycophenolic acid | Moderate | Antibiotics may reduce mycophenolate exposure via gut flora disruption |
| Pemetrexed | Moderate | NSAIDs/renally cleared drugs may increase pemetrexed toxicity — monitor if co-administered |
| Picosulfuric acid | Moderate | Antibiotic may reduce bowel preparation efficacy |
Note: Detailed prescribing warnings and contraindications were not available in this Evidence Pack. Please refer to the package insert for complete safety information before clinical use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic basis for ceftizoxime in gonococcal urethritis is exceptionally strong — its beta-lactamase stability and high PBP affinity directly address both sensitive and PPNG strains of N. gonorrhoeae, and this is supported by multiple prospective clinical studies and one head-to-head RCT against the current standard of care (ceftriaxone). The TxGNN prediction reflects genuine pharmacological alignment rather than statistical artifact.
To proceed, the following is needed:
- Formal India regulatory filing: No current licenses exist; pathway assessment under CDSCO (Central Drugs Standard Control Organisation) required for market entry
- Current resistance surveillance data: The most recent literature (2001, 2013) raises concerns about emerging cephalosporin-resistant N. gonorrhoeae strains; updated local/regional MIC data for Indian gonococcal isolates is essential before recommending as first-line therapy
- Mechanism of action documentation: Retrieve full DrugBank MOA entry (DB01332) and CDSCO/WHO prescribing data to complete the pharmacological dossier
- Safety package completion: Obtain and parse the full prescribing information (package insert) for key warnings, contraindications, and special population data (renal impairment dosing, pregnancy category)
- Formulation and route assessment: Ceftizoxime is administered IM/IV — confirm that a single-dose IM formulation consistent with STI clinic workflows is available or developable for the India market
- Comparison with current Indian STI treatment guidelines: Confirm whether ceftizoxime offers advantages over ceftriaxone (already likely available) in the Indian gonorrhea treatment landscape, particularly regarding drug supply and cost
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.